Adaptimmune Therapeutics plc has announced its financial results for the second quarter ended June 30, 2025. The company reported a significant decline in revenue for the three and six months ended June 30, 2025, with figures standing at $13.7 million and $21.0 million respectively, compared to $128.2 million and $133.9 million for the same periods in 2024. This decrease is attributed primarily to the termination of the Genentech collaboration in April 2024. However, product revenue has shown positive growth due to the commencement of sales following the FDA approval of TECELRA on August 1, 2024. In Q2 2025, TECELRA sales reached $11.1 million, with 16 patients invoiced, marking a growth of over 150% compared to Q1 2025. The company recorded a net loss of $30.3 million for the three months ended June 30, 2025, and $77.9 million for the six months, compared to profits of $69.5 million and $21.0 million for the corresponding periods in 2024. Adaptimmune has entered into a definitive agreement to sell several cell therapies, including TECELRA, to US WorldMeds for $55 million upfront and up to $30 million in future milestone payments. Following this transaction, the company has repaid its debt and is restructuring to maximize value from its remaining assets, including PRAME and CD70 directed T-cell therapies. The cash and cash equivalents are expected to be sufficient to meet planned operating requirements for the 12 months following the filing of the Quarterly Report for the second quarter of 2025.